Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp

                                       Silexion’s first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients...

Related Keywords

New York ,United States ,Israel ,Cayman Islands ,Modiin ,Israel General ,Israeli ,Ilan Levin ,Herzog Fox Neeman ,Gil Maman ,Exchange Commission ,Moringa Acquisition Corp ,Moringa Acquisition Corp Nasdaq ,Greenberg Traurig ,Nasdaq ,Silexion Ltd ,Crescendo Communications ,Acquisition Corp ,Chief Executive Officer ,Current Reports ,Law Offices ,Information About ,Proposed Transaction ,United States Securities ,Registration Statement ,Investor Relations ,Business Combination Agreement ,Nasdaq Capital Market ,Nasdaq Global Market ,Convertible Loans ,Note Concerning Forward Looking ,Financial Condition ,Securities Act ,Markets ,